Literature DB >> 7979203

Genes involved in hereditary nonpolyposis colorectal carcinoma.

L A Aaltonen1, P Peltomäki.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) (Lynch syndrome) accounts for a small proportion of the total colorectal cancer burden, yet represents the most common form of dominantly inherited colon cancer. Until recently, the diagnosis has been based on family history of colorectal and other intra-abdominal cancers. This has been problematic since chance clustering of such tumors cannot be excluded. On the other hand, not every HNPCC patients shows a dramatic family history of cancer. Genetic mapping of a locus for HNPCC to chromosome 2p and the observation that HNPCC tumors show instability of short tandem repeat sequences (replication errors, RER) rapidly led to the cloning of the predisposing gene, human MSH2 (hMSH2). Mutations of hMSH2 have been demonstrated to segregate in large HNPCC families with the cancer phenotype, thus providing convincing evidence that the gene indeed, when mutated, predisposes its carriers to colorectal and other intra-abdominal tumors. Localization of a second locus for HNPCC to chromosome 3p and the subsequent cloning of another predisposing gene, human MLH1 (hMLH1) give hope that a great majority of families can soon be diagnosed by molecular genetic methods.

Entities:  

Mesh:

Year:  1994        PMID: 7979203

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry.

Authors:  Mine S Cicek; Noralane M Lindor; Steven Gallinger; Bharati Bapat; John L Hopper; Mark A Jenkins; Joanne Young; Daniel Buchanan; Michael D Walsh; Loic Le Marchand; Terrilea Burnett; Polly A Newcomb; William M Grady; Robert W Haile; Graham Casey; Sarah J Plummer; Lisa A Krumroy; John A Baron; Stephen N Thibodeau
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

Review 2.  The cellular basis of metastasis.

Authors:  P Ruiz; U Günthert
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  Prognostic significance of hMLH1/hMSH2 gene mutations and hMLH1 promoter methylation in sporadic colorectal cancer.

Authors:  Yibaina Wang; Dandan Li; Xia Li; Chong Teng; Lin Zhu; Binbin Cui; Yashuang Zhao; Fulan Hu
Journal:  Med Oncol       Date:  2014-06-11       Impact factor: 3.064

4.  Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China.

Authors:  Guangxiao Li; Fulan Hu; Fengshun Yuan; Jialong Fan; Zhifu Yu; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Jiesheng Rong; Binbin Cui; Xinshu Dong; Huiping Yuan; Yashuang Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-06       Impact factor: 4.553

5.  Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.

Authors:  Frank Sinicrope; Nathan R Foster; Daniel J Sargent; Stephen N Thibodeau; Thomas C Smyrk; Michael J O'Connell
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

6.  The prognostic significance of polymorphisms in hMLH1/hMSH2 for colorectal cancer.

Authors:  Yibaina Wang; Guangxiao Li; Fulan Hu; Haoran Bi; Zhiwei Wu; Xiaojuan Zhao; Ye Li; Shuying Li; Dandan Li; Binbin Cui; Xinshu Dong; Yashuang Zhao
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

7.  Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.

Authors:  Madhuri Hegde; Maria Blazo; Belinda Chong; Tom Prior; Carolyn Richards
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

8.  Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?

Authors:  Eddy H J van Roon; Marjo van Puijenbroek; Anneke Middeldorp; Ronald van Eijk; Emile J de Meijer; Dianhdra Erasmus; Kim A D Wouters; Manon van Engeland; Jan Oosting; Frederik J Hes; Carli M J Tops; Tom van Wezel; Judith M Boer; Hans Morreau
Journal:  BMC Cancer       Date:  2010-05-05       Impact factor: 4.430

9.  The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.

Authors:  Valentina Turinetto; Paola Porcedda; Luca Orlando; Mario De Marchi; Antonio Amoroso; Claudia Giachino
Journal:  BMC Cancer       Date:  2009-08-12       Impact factor: 4.430

10.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.